CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Beigene Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Beigene Ltd
94 Solaris Avenue,, Camana Bay
Phone: (345) 949-4123p:345 949-4123 GRAND CAYMAN, BEJ  KY1-1108  Cayman Islands Ticker: 688235688235
Business Summary
BeiGene, Ltd. is a global biotechnology company. The Company is focused on developing and commercializing oncology medicines to improve treatment outcomes and expand access for patients worldwide. The Company has discovered and developed three approved medicines including, BRUKINSA, a small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) for the treatment of various blood cancers; tislelizumab, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; and pamiparib, a selective small molecule inhibitor of PARP1 and PARP2. BRUKINSA is a second-generation small molecule inhibitor of Bruton’s Tyrosine Kinase (BTK) designed to maximize BTK occupancy and minimize off-target binding effects. It has obtained approvals to market BRUKINSA in the United States, China, the European Union, the United Kingdom, Canada and Australia. The Company has in-licensed the rights to distribute 13 approved medicines for the China market.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/202312/31/2022Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Co-Founder, Executive Chairman of the Board, Chief Executive Officer John V.Oyler 55 10/1/2010 10/1/2010
President, Chief Operating Officer, General Manager - China XiaobinWu 61 4/1/2021 4/30/2018
Co-Founder, Non-Executive Director XiaodongWang 60 2/8/2016 2/8/2016
7 additional Officers and Directors records available in full report.

General Information
Number of Employees: 9,212 (As of 12/31/2022)
Outstanding Shares: 1,374,834,172 (As of 9/15/2023)
Shareholders: 49,681
Stock Exchange: SHA


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, February 21, 2024